Skip to main content

Table 4 Mean and standard deviation as well as the difference between the mean of drug evaluation indices before and after the intervention in the studied groups

From: Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis

Drugs

Index

I2

Begg and mazumdar rank correlation test

Mean ± SD before intervention (drug group)

Mean ± SD after intervention (drug group)

Mean difference and standard deviation before and after the intervention

Mycophenolate

MG-ADL

85.3

1.000

5.9 ± 0.87

7.5 ± 4.09

1.4 ± 0.9

SFEMG

0

–

71.5 ± 11.3

60.5 ± 13.1

0.9 ± 0.56

Anti-AChR antibodies

79.1

–

11.1 ± 2.1

5.5 ± 2.4

1.9 ± 1.5

QMGS

67.9

0.734

12.3 ± 0.71

8.1 ± 0.59

1.4 ± 0.77

Immunoglobulin or plasma exchange

MG-ADL

78.5

1.000

8.2 ± 1.3

4.4 ± 0.84

1.3 ± 0.63

SFEMG

43.5

1.000

82.2 ± 1.43

54.5 ± 27.5

1.5 ± 0.73

Anti-AChR antibodies

99.8

1.000

10.8 ± 4.6

52.7 ± 34.1

–2.006 ± 0.78

QMGS

98.6

0.391

11.2 ± 1.6

9.4 ± 1.8

0.62 ± 0.28

Corticosteroids

QMGS

99.4

–

7.08 ± 1.09

5.9 ± 2.2

1.64 ± 1.6